Litigation Settlement Agreement Finished Houston, TX, Jan. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) founding Director and Chief Executive Officer, Alex Blankenship,...

AngioSoma Confirms Status of Voting Control Houston, TX , Aug. 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has filed an amendment to its Form 10-K for the fiscal year ended...

AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™,...

AngioSoma, Inc. Announces Grant of Patent for Flagship Drug HOUSTON, TX, May 14, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship...